Nephrology
News
Missed visits during pandemic cause ‘detrimental ripple effects’
ACP president says doctors are already seeing the consequences of postponing care.
News
Further warning on SGLT2 inhibitor use and DKA risk in COVID-19
Five new cases of euglycemic diabetic ketoacidosis seen in T2D patients with acute COVID-19 illness.
News
ADA 2021 standards address financial hardship in diabetes
In the year of COVID-19, new ADA standards include assessment of socioeconomic challenges, individualization of type 2 diabetes treatment, and...
Conference Coverage
Finerenone’s heart benefits hold up in T2D patients without CVD
In the FIDELIO-DKD trial, cardiovascular benefits from a nonsteroidal mineralocorticoid antagonist held, regardless of CVD history, in T2D...
News
New guidelines address diabetes management in kidney disease
The Kidney Disease: Improving Global Outcomes synopsis document is aimed at primary care physicians and nonnephrology specialists, as well as...
Conference Coverage
Novel drug slows progression of diabetic kidney disease
Finerenone, a selective, nonsteroidal mineralocorticoid receptor antagonist, significantly reduced both renal and cardiovascular events, with good...
Original Research
Retrospective Review on the Safety and Efficacy of Direct Oral Anticoagulants Compared With Warfarin in Patients With Cirrhosis
A retrospective chart review of adult patients with cirrhosis taking either DOACs or warfarin found no statistically significant differences in...
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
Deaths sky high in hospitalized COVID patients with kidney injury
“We may be facing an epidemic of post–COVID-19 kidney disease and that, in turn, could mean much greater numbers of patients who require kidney...
Latest News
Real-world data show SGLT2 inhibitors for diabetes triple DKA risk
The findings are based on the use of three different SGLT2 inhibitors in Canada and the United Kingdom.